Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a serine lipase that is associated with low density lipoprotein (LDL) in human plasma. Substrates include oxidised phosphatidylcholine (PC), which is hydrolysed by Lp-PLA2 to lyso-PC and oxidised fatty acids. Both products are bioactive and proinflammatory, and implicated in monocyte infiltration into the developing plaque, deposition of foam cells, and plaque progression and instability. Lp-PLA2 has recently been shown to be a risk factor for coronary events in previously asymptomatic, hypercholesterolaemic men. A series of azetidinones was designed as potent and selective inhibitors of this enzyme; SB-222657 inhibited release of the chemotactic cleavage products from oxidised LDL, and SB-244323 reduced atherosclerotic plaque development in a 3 month rabbit study. A series of pyrimidones has been designed from a screening hit, and nanomolar inhibitors identified. Oral efficacy in inhibiting plasma Lp-PLA2 in rabbits has been demonstrated with a variety of structural classes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0014-827x(01)01011-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Association of PLA2G7 Gene Polymorphisms with Serum Lp-PLA2 Activity and Lipid Profile in Han Chinese Patients with Coronary Heart Disease.
Pharmgenomics Pers Med
December 2024
Cardiology Department, Hohhot First Hospital, Hohhot, 010030, People's Republic of China.
Purpose: This study aimed to investigate the distribution patterns of PLA2G7 gene variants in Han Chinese patients with coronary heart disease (CHD), and their relationships with serum lipoprotein-associated phospholipase A2 (Lp-PLA2) levels and lipid profiles.
Methods: A total of 93 han Chinese CHD patients were recruited. Serum Lp-PLA2 levels were determined using enzyme-linked immunosorbent assay (ELISA), while comprehensive analysis of PLA2G7 gene polymorphisms was conducted through whole-exome sequencing.
Unveiling the Synergy of Serum Lipoprotein-Associated Phospholipase A2 and PLA2G7 Gene Polymorphism (rs1805017) as Key Determinants of Coronary Artery Disease Risk and Severity: Implications for Early Intervention.
Cureus
November 2024
Biochemistry, Nizam's Institute of Medical Sciences, Hyderabad, IND.
Background Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a key enzyme selectively expressed in unstable, rupture-prone atherosclerotic plaques. Previous research has established a strong link between the gene and the development of coronary artery disease (CAD). While traditional risk factors like cholesterol levels and blood pressure are valuable, there remains a need for more specific biomarkers to identify individuals at heightened risk of atherosclerosis before the onset of clinical symptoms.
View Article and Find Full Text PDFAssociation of Lipoprotein-Associated Phospholipase A2 and Lipoprotein(a) With the Risk of Recurrence Stroke in Patients With Acute Ischemic Stroke.
J Clin Lab Anal
December 2024
Department of Neurology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Article Synopsis
- The study explores the prognostic significance of lipoprotein-associated phospholipase A2 (Lp-PLA2) and lipoprotein(a) (Lp(a)) in predicting long-term stroke recurrence in patients with acute ischemic stroke (AIS).
- A total of 580 AIS patients were monitored over two years, with results showing that 17.41% experienced stroke recurrence, highlighting key risk factors such as age, diabetes, and levels of Lp-PLA2 and Lp(a).
- The results suggest that using both Lp-PLA2 and Lp(a) together offers a more effective and cost-efficient method for assessing stroke recurrence risk than looking at these factors individually.
The Role of Lp-PLA2 as a Mediator Between Serum Magnesium and Zinc Levels and Cardiovascular Risk in Patients With Metabolic Syndrome.
Cureus
October 2024
Physiology, All India Institute of Medical Sciences, Deoghar, IND.
Background: Metabolic syndrome (MetS) is a collection of conditions that includes abdominal obesity, low high-density lipoprotein (HDL) levels, high triglycerides, hypertension, and impaired glucose metabolism, all of which are risk factors for cardiovascular diseases. Of the biomarkers above, lipoprotein-associated phospholipase A2 (Lp-PLA2) has been highlighted as a critical link between inflammation and the pathogenesis of atherosclerosis, which strongly predicts cardiovascular events. Micronutrients like magnesium and zinc are essential in maintaining metabolic and cardiovascular health, but these micronutrient deficiencies occur frequently among individuals with MetS.
View Article and Find Full Text PDFDiagnostic Utility of Combining Homocysteine, Lipoprotein-Associated Phospholipase A2, and the C-Reactive Protein-to-Albumin Ratio for Assessing Carotid Atherosclerosis and Plaque Stability in Patients with Essential Hypertension.
Cardiovasc Toxicol
November 2024
Department of Ultrasound in Medicine, Renhe Hospital, No. 1999, Changjiang West Road, Baoshan District, Shanghai, 200431, China.
Article Synopsis
- The study investigates how well homocysteine (HCY), lipoprotein-associated phospholipase A2 (LP-PLA2), and the C-reactive protein-to-albumin ratio (CAR) can predict carotid atherosclerosis (CAS) and plaque stability in patients with essential hypertension (EH).
- Out of 280 patients, those with CAS had significantly higher levels of HCY, LP-PLA2, and CAR compared to those without CAS, and these factors were found to be independent risk factors for CAS.
- When tested together, HCY, LP-PLA2, and CAR provided better diagnostic accuracy for CAS and plaque instability than when tested individually, indicating their combined use could improve patient assessment in
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!